Odulimomab
Modify Date: 2024-02-01 16:32:49
Odulimomab structure
|
Common Name | Odulimomab | ||
|---|---|---|---|---|
| CAS Number | 159445-64-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OdulimomabOdulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody. Odulimomab inhibits proliferation of T lymphocyte and shows protective effects against ischemia and reperfusion injury. Odulimomab can be used for the research of transplant rejection and immunological disease[1][2]. |
| Name | Odulimomab |
|---|
| Description | Odulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody. Odulimomab inhibits proliferation of T lymphocyte and shows protective effects against ischemia and reperfusion injury. Odulimomab can be used for the research of transplant rejection and immunological disease[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Odulimomab 在体外抑制 T 淋巴细胞增殖，以及 T 和自然杀伤细胞 (NK) 的细胞毒性和抗体产生[2]。 |
| In Vivo | Odulimomab (1.5 和 0.75 mg/kg；腹腔注射，第 1 次治疗 1.5 mg/kg，然后每天注射 0.75 mg/kg) 对缺血和再灌注损伤有保护作用，对移植后肾功能有所修复[1]。 Animal Model: Cynomolgus Monkeys with renal damage ischemia and kidney autotransplantation[1] Dosage: 1.5 and 0.75 mg/kg Administration: Intraperitoneal injection; 1.5 mg/kg for the first dose and after pedicle clamping followed by daily injection of 0.75 mg/kg until sacrifice Result: Decreased the creatinine level after ischemia and autotransplantation for 3 days and increased the potassium fraction reabsorption. |
| References |
| No Any Chemical & Physical Properties |